CD160 and cholangiocarcinoma: In the present study, PANX1 was shown to have a negative correlation with CD160 in various tumors, such as LGG (rho = −0.480, P < 2.2e-16), KIRP (rho = −0.371, P = 9e-11) and cholangiocarcinoma (CHOL) (rho = −0.41, P = 0.0137).